Otomycosis: A Systematic Review and Meta-Analysis of Prevalence and Causative Agents in the Era of Molecular Diagnostics Publisher Pubmed



Nazari T¹ ; Peymaeei F² ; Ghazi Mirsaid R³ ; Seiad Ahmadnezhad R² ; Bateni Shalmani A^{2, 4} ; Mahmoudi S² Show Affiliations
Source: BMC Infectious Diseases Published:2025

Abstract

Background: Molecular identification of fungal agents in otomycosis can provide a more accurate diagnosis and differentiation of species compared to conventional morphological methods. Previous reviews mostly relied on studies using conventional methods to explore the prevalence and distribution of otomycosis etiologies. We aim to estimate the prevalence and distribution of causative agents in otomycosis cases confirmed with molecular methods. Methods: We conducted a systematic search of PubMed, Scopus, Web of Science, and Google Scholar. We selected cross-sectional studies that reported causative agents of otomycosis and used molecular methods for identification of fungi. We appraised the quality of evidence using the JBI Checklist for Prevalence Studies. Clinical and mycological data were collected, and prevalence of otomycosis was estimated by meta-analysis. Results: Twenty studies reporting 1392 fungal isolates, consisting of 46 species from 11 distinct genera, were included in this review. The prevalence of otomycosis among clinically-suspected patients was 58.3% (95% CI: 41.4–73.5%). Aspergillus (75.8%, 95% CI: 70.3–80.6%) and Candida (15.3%, 95% CI: 8.7– 25.6%) were the most common etiologies. The most frequent Aspergillus species were A. niger (n = 352, 30.9%) and A. tubingensis (n = 270, 23.7%), and the most frequent Candida species were C. parapsilosis (n = 85, 39.7%) and C. albicans (n = 66, 30.8%). The quality of evidence was assessed to be poor in all included studies. Conclusions: Otomycosis is caused by a diverse set of species, predominantly from Aspergillus and Candida genera. Molecular identification techniques provide a more accurate understanding of the distribution of species associated with otomycosis. Clinical trial number: Not applicable. © The Author(s) 2025.